The 2019 European Lung Cancer Congress (ELCC), held in Geneva, Switzerland, took place on the 10–13 April. Leading researchers from around the world showcased the latest research and developments in lung cancer.

ELCC 2019

ELCC 2019

The 2019 European Lung Cancer Congress (ELCC), held in Geneva, Switzerland, took place on the 10–13 April. Leading researchers from around the world showcased the latest research and developments in lung cancer.

The LUNAR study: TTFields for NSCLC 0:48
The LUNAR study: TTFields for NSCLC
Ori Farber • 1 Apr 2019
Tumor treating fields as an anti-mitotic therapy 0:55
Tumor treating fields as an anti-mitotic therapy
Ori Farber • 1 Apr 2019
A STELLAR study: TTFields for malignant pleural mesothelioma 2:03
A STELLAR study: TTFields for malignant pleural mesothelioma
Ori Farber • 1 Apr 2019
Low-dose CT lung cancer screening: strengths and limitations 3:13
Low-dose CT lung cancer screening: strengths and limitations
Yeol Kim
Multiple-line TKIs to prolong chemo-free period in EGFRm+ NSCLC 1:49
Multiple-line TKIs to prolong chemo-free period in EGFRm+ NSCLC
Nicolas Girard
Enhancing the efficacy of immunotherapy in lung cancer 2:50
Enhancing the efficacy of immunotherapy in lung cancer
Wolf-Hervé Fridman
K-LUCAS: implementing lung cancer screening in Korea 4:11
K-LUCAS: implementing lung cancer screening in Korea
Yeol Kim
The IASLC: implementing personalized medicine in lung cancer 1:32
The IASLC: implementing personalized medicine in lung cancer
Giorgio Scagliotti
Liquid biopsy to improve NSCLC management 2:07
Liquid biopsy to improve NSCLC management
Laura Bonanno
Predicting response to checkpoint inhibitors and overcoming resistance in lung cancers 1:46
Predicting response to checkpoint inhibitors and overcoming resistance in lung cancers
Giorgio Scagliotti
Acute pulmonary toxicity in lung cancer 1:13
Acute pulmonary toxicity in lung cancer
Marina Garassino
Phase III real-world PACIFIC-R trial for NSCLC 1:06
Phase III real-world PACIFIC-R trial for NSCLC
Nicolas Girard
Implementation of low-dose CT lung cancer screening in France 1:24
Implementation of low-dose CT lung cancer screening in France
Olivier Leleu
What factors affect response to checkpoint inhibitors in lung cancer? 2:18
What factors affect response to checkpoint inhibitors in lung cancer?
Wolf-Hervé Fridman
Molecularly-guided treatment of advanced NSCLC: ALK inhibitor sequencing 2:10
Molecularly-guided treatment of advanced NSCLC: ALK inhibitor sequencing
Alice Tsang Shaw
Overcoming the challenges of precision medicine in lung cancer 1:53
Overcoming the challenges of precision medicine in lung cancer
Giorgio Scagliotti
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals